“We are confident that the application of TRIANNI’s proven transgenic human monoclonal antibody discovery platform technology to the veterinary field will add value to Zoetis’ product development programs,”

said Matthias Wabl, Ph.D., Trianni’s President and CEO.

“We appreciate TRIANNI’s experience in the development of therapeutic antibody platform capabilities and look forward to working with them on innovations for animal health,”

said Catherine A. Knupp, D.V.M., M.S., Executive Vice President and President, Research and Development at Zoetis.

“This collaboration will enhance our internally-developed pipeline of novel monoclonal antibodies and hasten the develop­ment of therapeutics that could transform the way veterinarians treat a range of diseases in animals.”

No financial details were disclosed.

Source: Zoetis

The post Trianni and Zoetis Announce Agreement to Develop a Transgenic Antibody Discovery Platform for Use in Animal Health appeared first on North America FarmQuip Magazine.